首页/数据集/Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

Mendeley Data2026-04-18 收录

银屑病药物临床试验

激酶抑制剂疗效评估

数据链接：

https://data.mendeley.com/datasets/f9mpn725rn 数据链接链接失效反馈

官方服务：

资源简介：

Supplemental material for Original Article titled "Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis".

应用场景：

创建时间：

2023-12-12

银屑病药物临床试验

患者报告结局

Supplemental materials for Bagel J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial

Mendeley Data50

Dataset from A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

银屑病药物临床试验

生物制剂疗效与安全性评估

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 week

NIAID Data Ecosystem30

Supplementary Materials for: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial

银屑病药物临床试验

TYK2抑制剂研究

This dataset contains supplementary materials for the following publication: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2

NIAID Data Ecosystem20

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

银屑病药物临床试验

自身免疫疾病靶向治疗

Background Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which

NIAID Data Ecosystem40

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

银屑病药物临床试验

儿科皮肤病

Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a P

Mendeley Data2020-11-12 更新30

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

资源简介：

相关数据集